BioSpace News Archive

Mallinckrodt plc, a global specialty pharmaceutical company, reported results for the second quarter ended June 30, 2023.1

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended June 30, 2023.

Meiji Seika Pharma Co., Ltd. announced that ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index, in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.

Phonak, a leading global provider of life-changing hearing solutions, is pleased to announce the latest additions to its successful Lumity hearing aid platform.

AlzeCure Pharma AB announced that a new scientific article has been published on the Phase I clinical results supporting the continued development of the lead candidate drug NeuroRestore ACD856.

Anteris Technologies Ltd, reported that DurAVR™ Transcatheter Heart Valve, a new class of biomimetic valve and the world’s only biomimetic, single-piece transcatheter aortic valve, was used to successfully to treat patients as part of the DurAVR™ THV Early Feasibility Study in the United States.

Empower Clinics Inc., is pleased to announce that it has closed a first tranche private placement of units of the Company, pursuant to which the Company issued 6,016,250 Units at a price of $0.04 per Unit for aggregate gross proceeds of $240,250.

Form Bio , the breakthrough AI-powered drug discovery platform, announced today its notable achievements and product advancements for the first half of 2023.

Olink Holding AB announced its unaudited financial results for the second quarter ended June 30, 2023.

Jnana Therapeutics today announced that the first participant has been dosed in its Phase 1b clinical trial of JNT-517 in individuals with phenylketonuria (PKU). JNT-517 is a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19 and is in development as a potential first-in-class oral treatment for PKU.